Ventas Management Discusses Q2 2012 Results - Earnings Call Transcript

Ventas (VTR)

Q2 2012 Earnings Call

July 26, 2012 10:00 am ET

Executives

Lori Wittman

Debra A. Cafaro - Chairman, Chief Executive Officer, Member of Executive Committee, and Member of Investment Committee

Raymond J. Lewis - President

Richard A. Schweinhart - Chief Financial Officer and Executive Vice President

John D. Cobb - Chief Investment Officer and Senior Vice President

Analysts

Richard C. Anderson - BMO Capital Markets U.S.

Jana Galan - BofA Merrill Lynch, Research Division

James Milam - Sandler O'Neill + Partners, L.P., Research Division

Ross T. Nussbaum - UBS Investment Bank, Research Division

Dan Bernstein - Stifel, Nicolaus & Co., Inc., Research Division

Quentin Velleley - Citigroup Inc, Research Division

Nicholas Yulico - Macquarie Research

Philip J. Martin - Morningstar Inc., Research Division

Omotayo T. Okusanya - Jefferies & Company, Inc., Research Division

Karin A. Ford - KeyBanc Capital Markets Inc., Research Division

Thomas C. Truxillo - BofA Merrill Lynch, Research Division

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Second Quarter 2012 Ventas Earnings Conference Call. My name is Derek and I'll be your operator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes. I would now like to turn the conference over to Ms. Lori Wittman, Vice President, Capital Market. Please proceed.

Lori Wittman

Thank you. Good morning, and welcome to the Ventas conference call to review the company's announcement today regarding its results for the quarter ended June 30, 2012.

As we start, let me express that all projections and predictions and certain other statements to be made during this conference call may be considered forward-looking statements within the meaning of the federal securities laws. These projections, predictions and statements are based on management's current beliefs, as well as on a number of assumptions concerning future events. The forward-looking statements are subject to many risks, uncertainties and contingencies, and stockholders and others should recognize that actual results may differ materially from the company's expectations, whether expressed or implied.

If you liked this article you might like

Ventas Medical REIT: Cramer's Top Takeaways

When it Drops, it's Time to Shop: Cramer's 'Mad Money' Recap (Tuesday 9/12/17)

Kindred Sells Skilled Nursing Facility Business for $700M

Don't Forget Why You Love Tech Stocks Like Amazon, Jim Cramer Explains

High-Dividend Ventas: A Dual Play on Real Estate and Health Care